Cover Image
市場調查報告書

AB Science SA:產品平台分析

AB Science SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 340850
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
AB Science SA:產品平台分析 AB Science SA - Product Pipeline Review - 2015
出版日期: 2015年08月26日 內容資訊: 英文 38 Pages
簡介

本報告提供AB Science SA的醫藥品開發平台現狀及各開發階段比較分析與藥物簡介,提供您標的,給藥途徑,分子類型,各作用機制的藥物評估,暫停中的開發計劃等資訊。

AB Science SA的基本資料

  • 概要
  • 主要資訊
  • 企業資料

AB Science SA:R&D概要

  • 主要的治療範圍

AB Science SA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

AB Science SA:開發中產品概況

  • 後期開發中產品
    • 申請駁回的/被撤消的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

AB Science SA:藥物簡介

  • masitinib
  • AB-8779
  • KIT816較量的小分子

AB Science SA:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

AB Science SA:最近的開發平台趨勢

AB Science SA:暫停中的計劃

AB Science SA:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • masitinib

AB Science SA:總公司和子公司的所在地

附錄

目錄
Product Code: GMDHC07477CDB

Summary

Global Markets Direct's, 'AB Science SA - Product Pipeline Review - 2015', provides an overview of the AB Science SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AB Science SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of AB Science SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of AB Science SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the AB Science SA's pipeline products

Reasons to buy

  • Evaluate AB Science SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of AB Science SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the AB Science SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of AB Science SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of AB Science SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of AB Science SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AB Science SA Snapshot
    • AB Science SA Overview
    • Key Information
    • Key Facts
  • AB Science SA - Research and Development Overview
    • Key Therapeutic Areas
  • AB Science SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • AB Science SA - Pipeline Products Glance
    • AB Science SA - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • AB Science SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • AB Science SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • AB Science SA - Drug Profiles
    • masitinib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AB-8779
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize KIT816 for Aggressive Mastocytosis, Seminoma and AML
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AB Science SA - Pipeline Analysis
    • AB Science SA - Pipeline Products by Target
    • AB Science SA - Pipeline Products by Route of Administration
    • AB Science SA - Pipeline Products by Molecule Type
    • AB Science SA - Pipeline Products by Mechanism of Action
  • AB Science SA - Recent Pipeline Updates
  • AB Science SA - Dormant Projects
  • AB Science SA - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • masitinib
  • AB Science SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AB Science SA, Key Information
  • AB Science SA, Key Facts
  • AB Science SA - Pipeline by Indication, 2015
  • AB Science SA - Pipeline by Stage of Development, 2015
  • AB Science SA - Monotherapy Products in Pipeline, 2015
  • AB Science SA - Filing rejected/Withdrawn, 2015
  • AB Science SA - Phase III, 2015
  • AB Science SA - Phase II, 2015
  • AB Science SA - Preclinical, 2015
  • AB Science SA - Discovery, 2015
  • AB Science SA - Pipeline by Target, 2015
  • AB Science SA - Pipeline by Route of Administration, 2015
  • AB Science SA - Pipeline by Molecule Type, 2015
  • AB Science SA - Pipeline Products by Mechanism of Action, 2015
  • AB Science SA - Recent Pipeline Updates, 2015
  • AB Science SA - Dormant Developmental Projects,2015
  • AB Science SA - Discontinued Pipeline Products, 2015
  • AB Science SA, Other Locations

List of Figures

  • AB Science SA - Pipeline by Top 10 Indication, 2015
  • AB Science SA - Pipeline by Stage of Development, 2015
  • AB Science SA - Monotherapy Products in Pipeline, 2015
  • AB Science SA - Pipeline by Top 10 Target, 2015
  • AB Science SA - Pipeline by Top 10 Route of Administration, 2015
  • AB Science SA - Pipeline by Top 10 Molecule Type, 2015
  • AB Science SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top